|
Kidney Failure, Chronic
|
0.300 |
GeneticVariation
|
disease |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Similarly, OCT2 (∼2-fold) and OCT3 (∼3-fold) showed increased protein expression in the kidneys of obese patients compared with those of nonobese individuals.
|
27401566 |
2016 |
|
Kidney Failure, Chronic
|
0.300 |
Biomarker
|
disease |
RGD |
Protein and mRNA expression levels of Oat1, Oat 3, Oct1, and Oct2 were significantly decreased in adenine-induced CRF rats.
|
23280877 |
2013 |
|
Kidney Diseases
|
0.300 |
Therapeutic
|
group |
CTD_human |
Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients.
|
22525860 |
2012 |
|
Kidney Failure, Chronic
|
0.300 |
GeneticVariation
|
disease |
GWASCAT |
New loci associated with kidney function and chronic kidney disease.
|
20383146 |
2010 |
|
Kidney Failure, Chronic
|
0.300 |
Biomarker
|
disease |
RGD |
Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.
|
12110012 |
2002 |
|
Hyperuricemia
|
0.210 |
Biomarker
|
disease |
BEFREE |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
|
30951542 |
2019 |
|
Hyperuricemia
|
0.210 |
Biomarker
|
disease |
RGD |
Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney.
|
15748710 |
2005 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
|
23280877 |
2013 |
|
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury.
|
22414646 |
2012 |
|
Kidney Failure
|
0.200 |
Biomarker
|
disease |
RGD |
Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats.
|
21167265 |
2011 |
|
Cholestasis, Extrahepatic
|
0.200 |
Biomarker
|
disease |
RGD |
Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2.
|
20814153 |
2010 |
|
Intrahepatic Cholestasis
|
0.200 |
Biomarker
|
disease |
RGD |
Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis.
|
19002567 |
2009 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Renal and hepatic transporter expression in type 2 diabetic rats.
|
19356064 |
2008 |
|
Endotoxemia
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia.
|
18313662 |
2008 |
|
Acute kidney injury
|
0.200 |
Biomarker
|
disease |
RGD |
Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats.
|
18612803 |
2008 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.
|
12110012 |
2002 |
|
Chronic Kidney Diseases
|
0.120 |
Biomarker
|
group |
BEFREE |
Further clinical studies are warranted with a broader range of OCT2 substrates to determine whether CKD may differentially affect tubular secretion of drugs especially in patients with advanced CKD.
|
28483424 |
2017 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
GWASDB |
Genome-wide association and functional follow-up reveals new loci for kidney function.
|
22479191 |
2012 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
GWASDB |
Genetic association for renal traits among participants of African ancestry reveals new loci for renal function.
|
21931561 |
2011 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
BEFREE |
Follow-up of the 23 new genome-wide-significant loci (P < 5 x 10(-8)) in 22,982 replication samples identified 13 new loci affecting renal function and CKD (in or near LASS2, GCKR, ALMS1, TFDP2, DAB2, SLC34A1, VEGFA, PRKAG2, PIP5K1B, ATXN2, DACH1, UBE2Q2 and SLC7A9) and 7 loci suspected to affect creatinine production and secretion (CPS1, SLC22A2, TMEM60, WDR37, SLC6A13, WDR72 and BCAS3).
|
20383146 |
2010 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
GWASDB |
New loci associated with kidney function and chronic kidney disease.
|
20383146 |
2010 |
|
Diabetes Mellitus
|
0.110 |
GeneticVariation
|
group |
GWASCAT |
Mapping eGFR loci to the renal transcriptome and phenome in the VA Million Veteran Program.
|
31451708 |
2019 |
|
Diabetes Mellitus
|
0.110 |
Biomarker
|
group |
BEFREE |
We investigated the influence of diabetes mellitus (DM), glycemic control with insulin, cimetidine (Oct2 inhibitor) and metformin (Oct2 substrate) on the kinetic disposition of GAB in rats.
|
29551575 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Mapping eGFR loci to the renal transcriptome and phenome in the VA Million Veteran Program.
|
31451708 |
2019 |